Rare disease

Artificial intelligence
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Benchling #Cancer research #Drug discovery #Machine learning #Rare disease

Latest eBook: AI and drug development

The latest eBook by DDW is out now. This 28-page eBook, sponsored by Benchling, examines the ways in which artificial intelligence and machine learning are expediting drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Benchling #Cancer research #Drug discovery #Machine learning #Rare disease

AI and drug development: Using AI and machine learning to expedite drug discovery

This latest eBook sponsored by Benchling features insight on how artificial intelligence is helping advance drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence How machine learning is being used across cancer research Why AI is critical to solving challenges in drug… Read More

#DDW eBooks #Intelligence

US Food and Drug Administration
#FDA #Gene therapy #Krystal Biotech #Rare disease

FDA approves first gene therapy for rare skin disorder

The US Food and Drug Administration has approved Krystal Biotech’s Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB). It is approved for treating wounds in patients six months of age and older with mutation(s) in the collagen type VII alpha… Read More

#News #Regulatory #Trending News

Lipid nanoparticle mRNA vaccine
#Advanced Therapies #Cell and gene therapy #Moderna #mRNA #Phase II trial #Rare disease

Positive initial data on first mRNA therapy for propionic acidemia

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase… Read More

#News #Trending News

siRNA
#FDA #Orphan drugs #Paediatrics #Rare disease #siRNA #SiSaf

Therapy for rare skeletal disorder granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to SiSaf’s small interfering RNA (siRNA) therapeutic for skeletal disorder Autosomal Dominant Osteopetrosis Type 2 (ADO2). In addition, due to the serious manifestations of this rare disease in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for… Read More

#News #Regulatory

#Agilent #Mitochondria #Neurodegenerative disorders #Neurology #Rare disease #Webinar

Watch now: Neuronal metabolism and early drug discovery

A new webinar is now available to watch anytime. CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. In her webinar, Dr García Macía discusses how failure in autophagy causes the accumulation of structurally and bioenergetically impaired neuronal mitochondria in the… Read More

Webinar date:
Brought to you by Agilent
#News

#Agilent #Mitochondria #Neurodegenerative disorders #Neurology #Rare disease

Neuronal metabolism and its impact on early drug discovery

CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. In her webinar, Dr García Macía discusses how failure in autophagy causes the accumulation of structurally and bioenergetically impaired neuronal mitochondria in the mouse model of CLN7 disease, and how the mitochondrial reactive oxygen species… Read More

Webinar date:
Brought to you by Agilent
#Webinars

Medical researcher
#Funding #Genetics / genomics #Investment #Paediatrics #Rare disease #SynaptixBio

‘Virtual’ biotech targets R&D funding on rare disease therapy

UK biotech firm SynaptixBio has secured £13.2 million to fund its development of the world’s first treatment for TUBB4A-related leukodystrophy, a rare, incurable and deadly disease. The company successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the last two years. It… Read More

#Business & Investment #News

Patient advocacy group
#Clinical trial design #Clinical trials #Decentralised clinical trials #Drug development #Patient centricity #Rare disease

Recruiting and retaining patients for successful drug development

Craig Stevens, Senior Patient Engagement Specialist, and Amanda Henkel, VP, Strategy from MEDiSTRAVA (an Inizio Company), delve into the challenges and opportunities that surround clinical trial design for rare diseases. The drug development process requires collaboration at all stages, and is particularly important in the rare disease setting, where in… Read More

#Exclusive Content

Business acquisition
#Mergers and acquisitions #Rare disease #Rhythm Pharmaeuticals #Xinvento

Rhythm Pharmaceuticals buys biotech focused on rare disease

Biopharmaceutical subsidiary Rhythm Pharmaceuticals Netherlands has acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).  CHI is a rare genetic disease in which cells secrete excess insulin, causing hypoglycemia, which can result in serious health outcomes including seizures, coma, permanent brain damage and death.   Xinvento… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Contract Research Organisations (CROs) #Machine learning #Rare disease #Rare Disease Day

How AI can be utilised to improve rare disease drug development

By Lucy Radley, Head of EU Regulatory Development, ProPharma. A rare disease is defined as a condition which affects less than one in 2000 people. Although individually they are very rare, collectively they are common with one in 17 people (around 3.5 million) in the UK being affected by a… Read More

#Exclusive Content #Opinion

Scientist in laboratory
#Orphan drugs #Rare disease #Rare Disease Day #Terebellum

Rare disease market access guide launched

A new strategic guide, intended to help manufacturers bring rare disease products to market, has been launched to mark Rare Disease Day (February 28). In the guide, Terebellum (a subsidiary of AscellaHealth) shares tips on how industry stakeholders can create an effective market access strategy, giving their treatment the best chance… Read More

#Business & Investment #News

Rare Disease Day
#Drug discovery #Rare cancers #Rare disease #Rare Disease Day

Five 2023 breakthroughs in drug discovery for rare diseases

Rare diseases are often overlooked for funding and research, but with various incentives and priority review programmes now in place, many companies are beginning to explore these unusual but often devastating conditions. This Rare Disease Day we provide an overview of the progress that has been made in… Read More

#News #Trending News

Rare disease
#Clinical development #Drug development #Drug discovery #Rare disease #Rare Disease Day

What is the biggest barrier to rare disease drug development?

Dr Asma Patel, Vice President of Integrated Services for Early Development at Quotient Sciences, reflects on the biggest barriers to rare disease drug development and how companies can overcome these. Despite improvements in regulatory support and commercial rewards, difficulties remain for drug developers in bringing rare disease drugs to market. Read More

#Exclusive Content #Opinion

#Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #Rare disease #Rare Disease Day #Thermo Fisher Scientific

Unlocking the potential of mRNA for the future treatment of rare diseases 

mRNA technology helped us to vaccinate the world against SARS-CoV-2. As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta, PhD, staff scientist in genetic sciences at Thermo Fisher… Read More

#Exclusive Content #Opinion

Duchenne muscular dystrophy
#Muscular dystrophy #National Institute for Health and Care Excellence (NICE) #Paediatrics #PTC Therapeutics #Rare disease

Rare muscular dystrophy drug to be funded in England and Wales

The National Institute for Health and Care Excellence (NICE) has published its Final Guidance recommending Translarna (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales.   Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged two years and older… Read More

#News #Regulatory